Skandinaviska Enskilda Banken (SEB)
RXRX icon

Skandinaviska Enskilda Banken (SEB)’s Recursion Pharmaceuticals RXRX Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-15,500
Closed -$119K – 965
2023
Q3 		$119K Sell
15,500
-32,300
-68% -$322K ﹤0.01% 859
2023
Q2 		$358K Sell
47,800
-400
-0.8% -$2.8K ﹤0.01% 818
2023
Q1 		$321K Buy
+48,200
New +$382K ﹤0.01% 800

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s RXRX Position: Q4 2023 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Recursion Pharmaceuticals (RXRX) in Q4 2023, closing a stake of 15,500 shares — an estimated $119K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in RXRX in Q1 2023 and held it in 3 quarters. The position peaked at $358K in Q2 2023. 199 funds tracked by Wall St. Rank hold RXRX as of Q4 2023.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Recursion Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 15,500 Recursion Pharmaceuticals shares in Q4 2023, an estimated $119K.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Recursion Pharmaceuticals in Q1 2023 and held it in 3 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s Recursion Pharmaceuticals position peaked at $358K in Q2 2023.
  • 199 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2023.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q4 2023, filed 14 Feb 2024.